New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer
Open Access
- 17 November 2015
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 113 (11) , 1607-1614
Abstract
Nature - the world's best science and medicine on your desktopKeywords
This publication has 41 references indexed in Scilit:
- Metformin is associated with reduced risk of pancreatic cancer in patients with type 2 diabetes mellitus: A systematic review and meta-analysisDiabetes Research and Clinical Practice, 2014
- Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational StudiesCurrent Drug Safety, 2013
- Adrenomedullin is Up-regulated in Patients With Pancreatic Cancer and Causes Insulin Resistance in β Cells and MiceGastroenterology, 2012
- Use of HbA1c in the diagnosis of diabetesBMJ, 2012
- Prediabetes: a high-risk state for diabetes developmentThe Lancet, 2012
- Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trialsDiabetologia, 2010
- Metformin Disrupts Crosstalk between G Protein–Coupled Receptor and Insulin Receptor Signaling Systems and Inhibits Pancreatic Cancer GrowthCancer Research, 2009
- Prediagnostic Plasma C-Peptide and Pancreatic Cancer Risk in Men and WomenCancer Epidemiology, Biomarkers & Prevention, 2007
- Validation studies of the health improvement network (THIN) database for pharmacoepidemiology researchPharmacoepidemiology and Drug Safety, 2006
- The Association Between Diabetes and Hepatocellular Carcinoma: A Systematic Review of Epidemiologic EvidenceClinical Gastroenterology and Hepatology, 2006